NASDAQ: SABS - SAB Biotherapeutics, Inc.

半年間の収益性: -44.84%
セクタ: Healthcare

プロモーションスケジュール SAB Biotherapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

さらに詳しく
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Выручка 0.0034
EBITDA -0.0082
Число акций ао 0.00552 млрд
P/S 0.3507
P/BV 0.5539
EV/EBITDA -0.1569
Цена ао 4.17
ISIN US78397T1034
Сайт https://www.sabbiotherapeutics.com
Валюта usd
IPO date 2021-02-09
Sector Health Care
Industry Biotechnology
Валюта отчета usd
1日あたりの価格変動: -5.02% (2.5899)
週ごとの価格変動: -7.87% (2.67)
月ごとの料金変更: -12.77% (2.82)
3ヶ月間の価格変動: -14.29% (2.87)
半年間の価格変動: -44.84% (4.46)
年間の価格変動: +260.7% (0.682)
3年間の価格推移: -75.57% (10.07)
年初からの価格変動: +170.33% (0.91)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 1.75 8
P/BV 0.0684 10
P/E 0 0
EV/EBITDA 1.36 10
合計: 6

効率

名前 意味 学年
ROA, % -50.27 0
ROE, % -73.64 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.1721 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % -34.15 0
収益性 Ebitda, % 318.66 10
収益性 EPS, % 3428.04 10
合計: 8
さらに詳しく

機関 音量 共有, %
Marshall Wace LLP 4585282 49.7
RA Capital Management, L.P. 2374081 25.73
COMMODORE CAPITAL LP 1831746 19.86
RTW Investments LP 917828 9.95
BVF Inc. 917828 9.95
Sessa Capital IM, L.P. 458457 4.97
Vanguard Group Inc 99614 1.08
First Premier Bank 80754 0.88
Pathstone Holdings, LLC 50651 0.55
Geode Capital Management, LLC 35636 0.39

ETF 共有, % 年間の利益率, % 配当金, %
iShares Micro-Cap ETF 0.00541 43.316995205115 1.54048



スーパーバイザー 役職 支払い 生年
Mr. Samuel J. Reich CEO & Executive Chairman 363.2k 1975 (49 年)
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 402.56k 1966 (58 年)
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 25k 1956 (68 年)
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 774.45k 1973 (51 年)
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer N/A
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 443.2k 1971 (53 年)
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Mark W. Conley Interim Chief Financial Officer

住所: United States, Sioux Falls. SD, 2100 East 54th Street North - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.sabbiotherapeutics.com